ProMetic Life Sciences’ (PLI) “Speculative Buy” Rating Reaffirmed at TD Securities
TD Securities restated their speculative buy rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research note published on Wednesday. They currently have a C$4.50 price target on the stock.
A number of other research firms have also weighed in on PLI. Royal Bank Of Canada reissued an outperform rating on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. Scotiabank reissued an outperform rating and set a C$5.00 price target on shares of ProMetic Life Sciences in a research report on Thursday, August 25th. Finally, CIBC dropped their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of C$4.84.
ProMetic Life Sciences (TSE:PLI) opened at 2.96 on Wednesday. The firm’s market capitalization is $1.79 billion. The stock’s 50 day moving average is $2.89 and its 200 day moving average is $3.02. ProMetic Life Sciences has a 1-year low of $1.58 and a 1-year high of $3.62.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Stock Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related stocks with our FREE daily email newsletter.